

## REMINDER OF UNMARKETABLE PARCEL SHARE BUY-BACK

MELBOURNE, 22 January 2021: Investors are advised that on 14 December 2020, Anatara Lifesciences Limited (**Anatara**) (ASX:ANR) announced details of an off-market share buy-back facility (**Buy-Back Facility**) to buy-back all of the shares held by shareholders who held unmarketable parcels of shares in the Company (**Eligible Shareholders**) as at 7:00pm (Melbourne time) on Friday, 11 December 2020 (**Record Date**).

In accordance with the terms of the Buy-Back Facility, Eligible Shareholders have until 7:00pm (Melbourne time) Friday, 5 February 2021 (**Closing Time**) to either:

- opt-out of the Buy-Back Facility; or
- increase their shareholding to more than a marketable parcel.

Eligible Shareholders that do not exercise either of these options by the Closing Time will have their Anatara shares bought back by the Company at the volume-weighted average price for the five-day trading period preceding the Record Date, being \$0.178 per Anatara share.

Anatara has sent all relevant information and documentation to Eligible Shareholders. Eligible Shareholders who wish to retain their shares must complete and sign their personalised Share Retention Form and forward it to Anatara's share registry, Computershare Investor Services Pty Ltd by mail to GPO Box 52, Melbourne, Victoria, 30001 or by email to [corpactpprocesssing@computershare.com.au](mailto:corpactpprocesssing@computershare.com.au) in a timely manner so that it is received by or before the Closing Time.

The key dates for the Buy-Back Facility is included below.

7:00pm (Melbourne time) Friday, 11 December 2020	Record Date
Monday, 14 December 2020	Formal announcement of the Buy-Back Facility to the ASX
Friday, 18 December 2020	Despatch of Shareholder Letters and Share Retention Forms to Eligible Shareholders
7:00pm (Melbourne time) Friday, 5 February 2021	Closing Time for receipt of Share Retention Forms / period to opt-out of Buy-Back Facility
Tuesday, 9 February 2021	Shares bought back through the Buy-Back Facility will be cancelled
Wednesday, 10 February 2021	Announcement of outcome of the Buy-Back Facility to the ASX
As soon as practicable post Friday, 12 February 2021	Eligible Shareholders whose shares were bought back under the Buy-Back Facility will have proceeds remitted to them and will be sent documentation advising them of the number of shares bought back and the amount of proceeds remitted.  Proceeds will be remitted in Australian dollars to the bank account that the Eligible Shareholder has registered with Computershare. If no bank account is registered, proceeds will be remitted by cheque mailed to the address that the shareholder has registered with Computershare.

Anatara Lifesciences Limited  
Registered Office

Level 3, 62 Lygon Street, Carlton South, VIC, 3053, Australia

Administration and R&D

343 Royal Parade, Parkville, Melbourne, VIC 3052, Australia

Email [info@anatara.com](mailto:info@anatara.com) | Website [anataralifesciences.com](http://anataralifesciences.com)

Please refer to the Company's announcement dated 14 December 2020 for further details about the buy-back of unmarketable parcels of shares. Anantara reserves the right to modify the dates of the Buy-Back Facility, or to suspend or terminate the Buy-Back Facility. Any modification, suspension, or termination will be notified by written notice to the ASX.

Eligible Shareholders whose shares are brought back under the Buy-Back Facility will have their proceeds remitted to them and will be sent documentation advising them of the number of shares sold and the amount of proceeds remitted as soon as practicable following 12 February 2021.

For further information, please contact the Anantara Buy-Back Information Line on 1300 850 505 (from within Australia) or +61 3 9415 4000 (from outside Australia) between Monday, 14 December 2020 and Friday, 19 February 2021, between the hours of 8:30am to 5:00pm Monday – Friday (Melbourne time).

This announcement has been authorised by Anantara's Board of Directors.

**For more information please contact:**

<b>General inquiries</b>	
Steven Lydeamore CEO, Anantara Lifesciences Ltd +61 (0) 438 027 172 slydeamore@anatara.com	Sue MacLeman Chair, Anantara Lifesciences Ltd +61 (0) 437 211 200 smacleman@anatara.com

**About Anantara Lifesciences Ltd**

Anantara Lifesciences Ltd (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anantara is a life sciences company with expertise in developing products for animal and human health. Anantara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.

**Disclaimer**

The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Anantara Lifesciences Ltd, ACN 145 239 872 (Company). In preparing this presentation, the Company did not take into account the investment objectives, financial situation, and particular needs of any particular investor. Further advice should be obtained from a professional investment adviser before taking any action on any information dealt with in the presentation. Those acting upon any information without advice do so entirely at their own risk. Whilst this presentation is based on information from sources which are considered reliable, no representation or warranty, express or implied, is made or given by or on behalf of the Company, any of its directors, or any other person about the accuracy, completeness or fairness of the information or opinions contained in this presentation. No responsibility or liability is accepted by any of them for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this presentation. Neither the Company nor any of its directors, officers, employees, advisers, associated persons or subsidiaries are liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon any statement in this presentation or any document supplied with this presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly disclaimed. Any opinions expressed reflect the Company's position at the date of this presentation and are subject to change.

Anantara Lifesciences Limited

Registered Office

Level 3, 62 Lygon Street, Carlton South, VIC, 3053, Australia

Administration and R&D

343 Royal Parade, Parkville, Melbourne, VIC 3052, Australia

Email [info@anatara.com](mailto:info@anatara.com) | Website [anataralifesciences.com](http://anataralifesciences.com)

